StrategiesBrazilMexico WHO guidelinesAppliedNot Applied All generics are bioequivalentSince 1999Since 2005 Highly positioned in the policy agenda YesNo Medicines Regulatory Agency role ANVISA: Medicines only Highly positioned Financial support to promote generic medicines COFEPRIS: Sanitary risks in general Low positioned Overwhelmed by responsibilities National Pharmaceutical IndustryKey player in supporting the policy Fragmented and was not an active player Potential reasons why generic market share increased faster in Brazil than in Mexico
{}